1H 2018 Life Science Markets Update
Madison Park Group (MPG) actively tracks the life sciences software landscape and has been instrumental in strategic deals across the drug development & commercial spectrum
2022 saw continued investment in emerging players and big strategic bets by many established life sciences software platforms. From clinical discovery to commercialization, advancing digital solutions remains central to pharma and med device manufacturers. The plethora of real world evidence data collected pre-market and post-market continues to demand innovation and a data analytics ecosystem where both software and services players co-exist. We are excited about the huge potential for further strategic consolidation and high growth opportunities for many new entrants.
Madison Park Group actively tracks the life sciences software and services landscape and has been instrumental in strategic deals across the drug development & commercialization spectrum. We’ve noticed a number of recent trends and developments: